Compare PMTS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | AGEN |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.4M | 274.8M |
| IPO Year | 2015 | 1999 |
| Metric | PMTS | AGEN |
|---|---|---|
| Price | $28.24 | $8.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $27.67 | $14.50 |
| AVG Volume (30 Days) | 112.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 0.34 | ★ 0.96 |
| Revenue | ★ $312,189,000.00 | $42,877,086.00 |
| Revenue This Year | $9.95 | $107.63 |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $83.46 | ★ $8.43 |
| Revenue Growth | 12.27 | ★ 89.95 |
| 52 Week Low | $10.81 | $2.71 |
| 52 Week High | $31.25 | $8.85 |
| Indicator | PMTS | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.69 | 59.43 |
| Support Level | $27.00 | $2.97 |
| Resistance Level | $31.25 | $8.70 |
| Average True Range (ATR) | 1.04 | 0.57 |
| MACD | -0.30 | -0.08 |
| Stochastic Oscillator | 55.25 | 63.66 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.